Navellier & Associates’s Catalyst Pharmaceutical CPRX Stock Holding History

Navellier & Associates’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$312K	Buy	12,616 +872	+7%	+$20.8K	0.03%	278
2025 Q4	$274K	Sell	11,744 -1,602	-12%	-$35.7K	0.03%	284
2025 Q3	$263K	Buy	13,346 +822	+7%	+$16.9K	0.03%	324
2025 Q2	$272K	Hold	12,524	–	–	0.03%	273
2025 Q1	$304K	Sell	12,524 -1,639	-12%	-$36.9K	0.04%	254
2024 Q4	$296K	Buy	14,163 +1,869	+15%	+$40.2K	0.04%	277
2024 Q3	$244K	Sell	12,294 -1,698	-12%	-$31.5K	0.03%	294
2024 Q2	$217K	Buy	13,992 +164	+1%	+$2.55K	0.03%	320
2024 Q1	$220K	Sell	13,828 -140,449	-91%	-$2.12M	0.03%	317
2023 Q4	$2.59M	Buy	154,277 +17,663	+13%	+$241K	0.39%	80
2023 Q3	$1.6M	Buy	136,614 +11,170	+9%	+$149K	0.27%	97
2023 Q2	$1.69M	Buy	125,444 +718	+0.6%	+$10.3K	0.33%	91
2023 Q1	$2.07M	Buy	124,726 +15,240	+14%	+$251K	0.44%	83
2022 Q4	$2.04M	Buy	109,486 +4,448	+4%	+$68.5K	0.41%	78
2022 Q3	$1.35M	Buy	+105,038	New	+$1.24M	0.3%	91

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Navellier & Associates's CPRX Position: Q1 2026 in Review

Navellier & Associates increased its Catalyst Pharmaceutical (CPRX) stake by 7.4% in Q1 2026, buying an estimated $20.8K and bringing the position to 12,616 shares worth $312K. The position accounts for 0.03% of the portfolio, ranked #278.

Navellier & Associates first reported a position in CPRX in Q3 2022 and has held it in 15 quarters since. The position peaked at $2.59M in Q4 2023. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Navellier & Associates held 12,616 shares of Catalyst Pharmaceutical worth $312K as of Q1 2026.
Navellier & Associates bought 872 Catalyst Pharmaceutical shares in Q1 2026, an estimated $20.8K.
Catalyst Pharmaceutical made up 0.03% of Navellier & Associates's portfolio in Q1 2026, its #278 holding.
Navellier & Associates first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 15 quarters since.
Navellier & Associates's Catalyst Pharmaceutical position peaked at $2.59M in Q4 2023.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Navellier & Associates's 13F filing for Q1 2026, filed 7 May 2026.